Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-03-08
2011-03-08
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S144100
Reexamination Certificate
active
07901678
ABSTRACT:
The present invention provides pharmaceutical compositions composing, as an active ingredient, a substance capable of activating the γ chain of Fc receptors (FcRγ) (provided that the substance is not an immunoglobulin for intravenous injection), and agents for stimulating myelinogenesis. The invention also provides agents for stimulating the differentiation of oligodendroglial precursor cells, agents for activating Fyn tyrosine kinase, and agents for stimulating the expression of myelin basic protein, all comprising a substance capable of activating FcRγ as an active ingredient. Further, the invention provides a method of detecting myelinogenetic oligodendroglias or precursor cells thereof which comprises using the expression of FcRγ in oligodendroglias or precursor cells thereof as an indicator.
REFERENCES:
patent: 5985276 (1999-11-01), Lindhofer et al.
patent: 6210668 (2001-04-01), Lindhofer et al.
patent: 6551592 (2003-04-01), Lindhofer et al.
patent: 9-145714 (1997-06-01), None
patent: 10-179151 (1998-07-01), None
patent: 10-182487 (1998-07-01), None
patent: 2000-135089 (2000-05-01), None
patent: 2001-13448 (2001-05-01), None
patent: 2001-133448 (2001-05-01), None
Iruretagoyena et al. Activating and inhibitory Fcgamma receptors can differentially modulate T cell-mediated autoimmunity. . Eur J Immunol. Aug. 2008;38(8):2241-50.
Noseworthy et al . IV immunoglobulin does not reverse established weakness in MS.. Neurology. Oct. 24, 2000;55(8):1135-43.
Stangel et al. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J. Neurol Neurosurg Psychiatry 2000, 68:89-92.
Fazekas et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997, 349:589-93.
Cochlovius et al Therapeutic Antibodies After years of promise, magic bullets appear to be on the upswing. Modern Drug Discovery, 2003, pp. 33-34 and 37-38.
Umemori et al.lnitial events of myelination involve Fyn tyrosine kinase signalling. Nature. 1994, 367:572-576.
Nakahara et al. Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. J Clin Invest. 2009;119(1):169-181.
Esther et al. K. Neuropathol. Exp. Neurol. 2005, 65:304-311.
Hartung et al. J. Neurol. 2005, 252(Supp. 5):V/30-V/37.
Graziano et al. The Journal of Immunology, 1995, 155:4996-5002.
Nakahara et al. Developmental Cell, 2003, 4:841-852.
Subramaniam Sriram, et al., “Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis”, American Neurological Association, Annals of Neurology vol. 58, No. 6, Dec. 2005, pp. 939-945.
Jin Nakahara, et al., “Fc Receptor-Positive Cells in Remyelinating Multiple Sclerosis Lesions”, J Neuropathol Exp Neurol, vol. 65, No. 6, Jun. 2006, pp. 582-591.
John D. Cahoy, et al., “A Transcriptome Database for Astrocytes, Neurons, and Oligodendrocytes: A New Resource for Understanding Brain Development and Function”, The Journal of Neuroscience, Jan. 2, 2008, pp. 264-278.
J. D. Cahoy, et al., “A Transcriptome Database for Astrocytes, Neurons, and Oligodendrocytes: A New Resource for Understanding Brain Development and Function”, Online Supplemental data for J Neurosci 28: 264-78 (2008), 1 page.
Christopher Lock, et al., “Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis”, Nature Medicine, vol. 8, No. 5, May 2002, pp. 500-508.
Jin Nakahara, et al., “Signaling via Immunoglobulin Fc Receptors Induces Oligodendrocyte Precursor Cell Differentiation”, Developmental Cell, vol. 4, Jun. 2003, pp. 841-852.
Christopher B. Lock, et al., “Gene microarray analysis of multiple sclerosis lesions”, Trends in Molecular Medicine, vol. 9, No. 12, Dec. 2003, pp. 535-541.
Chika Seiwa, et al., Restoration of FcRy/Fyn Signaling Repairs Central Nervous System Demyelination, Journal of Neuroscience Research, 2007, pp. 954-966.
Otto Hommes, et al., “IVIG trials in MS. Is albumin a placebo?”, J. Neurol (2009), 256: 268-270.
Jacqueline T. Chen, et al., “Magnetization Transfer Ratio Evolution with Demyelination and Remyelination in Multiple Sclerosis Lesions”, Annals of Neurology, vol. 63, No. 2, Feb. 2008; 254-262.
Sha Mi, et al., “LINGO-1 negatively regulates myelination by oligodendrocytes”, Nature Neuroscience, vol. 8, No. 6, Jun. 2005; 745-751.
Sha Mi, et al., “Promotion of Central Nervous System Remyelination by Induced Differentiation of Oligodendrocyte Precursor Cells”, Annals of Neurology, vol. 65, No. 3, Mar. 2009; 304-315.
Sha-Mi, “LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis”, Nature Medicine, vol. 13, No. 10, Oct. 2007; 1228-1233.
Heather A. Arnett, et al., “bHLH Transcription Factor Olig1 is Required to Repair Demyelinated Lesions in the CNS” Science, vol. 306, pp. 2111-2115, 2004.
Signe Humle Jorgensen, et al., “Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis”, Journal of Neurological Sciences, vol. 233, pp. 61-65, 2005.
Felix Schlachetzki, et al., “Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier”, Journal of Neurochemistry, vol. 81, pp. 203-206, 2002.
Glenn K. Matsushima, et al., “The Nuorotoxicant, Cuprizone, as a Model to Study Demyelination and Remyelination in the Central Nervous System”, Brain Pathology 11: 107-116 (2001).
Markus Kipp, et al., “The cuprizone animal model: new insights into an old story”, Acta Neuropathol (2009) 118: 723-736.
Sha Mi, et al., “LINGO-1 and its role in CNS repair”, The International Journal of Biochemistry & Cell Biology, 40 (2008), pp. 1971-1978.
Aiso Sadakazu
Asou Hiroaki
Nakahara Jin
Haddad Maher M
Keio University
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Medicinal compositions containing Fc receptor γ chain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicinal compositions containing Fc receptor γ chain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal compositions containing Fc receptor γ chain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2719571